Hansa has provided a clinical update and top-line results ahead of the Q3 results.
Fiskars lowers its guidance for 2023 and published preliminary information of Q3.
Ett av branschens starkaste tillväxtbolag med ett transformativt förvärv till låg värdering Sun4Ener...
Bivoca has signed a direct bill contract providing access to DiviTum TKa to appropriate patients tre...
Redeye comments on today’s news that Bioservo is exploring alternatives to accelerate commercializat...
Scanfil cut FY ‘23 guidance down a bit, but the news wasn’t big and EBIT should stay above EUR 60m a...
Redeye provides a research update following the Q4 report published by Newbury yesterday.
Redeye comments on Nanexa’s preliminary key financial information for Q3.
Redeye provides a short update following Faron’s recent clinical data update from the phase I/II BEX...
Stabil tillväxt med imponerande marginalexpansion Förvärv har historiskt stått för två tredjedelar a...
Redeye leaves an initial comment following the Q4 report published by Newbury this morning.
Den virtuella satellitsnätsoperatören Wyld Networks ("Wyld") påbörjade leverans av moduler vilket be...
With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread g...
Scanfil downgraded its 2023 revenue guidance midpoint by 3% on 10 October.
IRLAB is collaborating with two US-based advisory groups, Clintrex (clinical research company) and P...
Q3e: Clean EBIT of SEK -28m Pulp futures sharply up – Chinese pulp prices up 19% Fair value range: S...
Gradual q-o-q margin improvement should continue New estimates reflect downsizing of tobacco busines...
Q3 due 8 Nov, we expect weaker growth A bit more cautious on growth and profitability Share trading ...
Konjunkturokänslig verksamhet i en expansiv region, innovativ och ledande hållbarhet, stabil utdelni...
Under Q2 mjuklanserades bolagets nikotinpåsar i utvalda butiker och inom läkemedelsutveckling är Emp...
